Conditions: Diabetic Nephropathy
Keywords: Diabetic nephropathy type 2 diabetes albuminuria chemokine antagonist
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 226
Healthy volunteers: no

Brief summary:
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: PF-04634817 intervention 2: Placebo
Intervention descriptions: intervention 1: Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function intervention 2: Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function

Protocol document: